Agios Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
37.8%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$5.63next fiscal year
Monitoring Framework
Key Performance Indicators
Mitapivat Net Revenues (Worldwide) Quarterly20.7MTarget: Clear path to profitability with potential to achieve over $1 billion in peak global sales
AQVESME REMS-Certified Prescriptions (U.S.) Quarterly242.0
Cash, Cash Equivalents, and Marketable Securities Quarterly1B
Watch Items
- FDA sNDA Filing Acceptance for Mitapivat in Sickle Cell DiseaseTrigger: FDA filing review decision expected in Q3 2026Action: Monitor regulatory updates and potential accelerated approval timeline
- Tebapivat Phase 2 Topline Results in Sickle Cell DiseaseTrigger: Topline readout expected in H2 2026Action: Evaluate efficacy and safety profile compared to mitapivat
- Tebapivat Development in Lower-Risk Myelodysplastic Syndromes (LR-MDS)Trigger: Discontinuation of development in LR-MDS due to failure to meet efficacy targetsAction: Assess impact on pipeline valuation and redirect resources to other indications
Research as of 20 Jun 2026